Galderma successfully completes the acquisition of ALASTIN Skincare®

Galderma has received antitrust clearance from the US authorities and has completed the acquisition of ALASTIN Skincare®, Inc. (“ALASTIN”), a specialty aesthetics company, dedicated to developing innovative and clinically-tested physician-dispensed skincare products.The transaction was previously announced on November 29, 2021. Galderma remains at the forefront of the rapidly expanding global skincare market and has consistently delivered strong results.The consumer interest and acceptance of aesthetic procedures is increasing rapidly, and the addition of ALASTIN’s synergistic portfolio and expertise in science-based skincare will increase Galderma’s ability to serve the needs of both consumers and professionals.The patented TriHex Technology® backs up ALASTIN’s product offerings, a proprietary blend of peptides and active botanicals to support the appearance of rejuvenated skin. In 2020, ALASTIN was named the fastest-growing brand in the professional skincare market in the U.S and its performance has been marked by rapid and constant sales growth.This acquisition will enhance Galderma’s integrated dermatology platform with a comprehensive collection of scientifically-proven products for daily skincare regimens and peri-procedural use, and underscores the company’s commitment to be the partner of choice for aesthetic professionals.